Announcement • Apr 23
AddLife AB (publ) (OM:ALIF B) acquired CoaChrom Diagnostica GmbH. AddLife AB (publ) (OM:ALIF B) acquired CoaChrom Diagnostica GmbH on April 22, 2026. As part of the acquisition, CoaChrom will become part of AddLife’s Business Area Labtech. CoaChrom will continue to operate under its own brand and with a high degree of operational independence, in line with AddLife’s decentralized business model. The acquisition is expected to have a marginal positive impact on AddLife’s earnings per share during the current financial year.
For the period ending December 31, 2025, CoaChrom Diagnostica GmbH reported total revenue of approximately €10 million.
AddLife AB (publ) (OM:ALIF B) completed the acquisition of CoaChrom Diagnostica GmbH on April 22, 2026. Announcement • Feb 09
AddLife AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026 AddLife AB (publ) announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 02, 2026 Announcement • Feb 04
AddLife AB (publ) to Report Fiscal Year 2026 Results on Feb 03, 2027 AddLife AB (publ) announced that they will report fiscal year 2026 results on Feb 03, 2027 Announcement • Oct 23
AddLife AB (publ) to Report Q3, 2026 Results on Oct 21, 2026 AddLife AB (publ) announced that they will report Q3, 2026 results on Oct 21, 2026 Announcement • Mar 27
AddLife AB (publ) Announces Håkan Roos Declines Re-Election to the Board AddLife AB (publ) announced that Håkan Roos has declined re-election to the board. Announcement • Mar 10
AddLife AB (publ) to Report Fiscal Year 2024 Final Results on Apr 04, 2025 AddLife AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 04, 2025 Announcement • Feb 06
AddLife AB (publ), Annual General Meeting, May 08, 2025 AddLife AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: stockholm Sweden New Risk • Oct 24
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin). Reported Earnings • Oct 23
Third quarter 2024 earnings released: EPS: kr0.20 (vs kr0.20 in 3Q 2023) Third quarter 2024 results: EPS: kr0.20 (down from kr0.20 in 3Q 2023). Revenue: kr2.34b (up 1.1% from 3Q 2023). Net income: kr24.0m (down 4.0% from 3Q 2023). Profit margin: 1.0% (in line with 3Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 16
Second quarter 2024 earnings released: EPS: kr0.59 (vs kr0.26 in 2Q 2023) Second quarter 2024 results: EPS: kr0.59 (up from kr0.26 in 2Q 2023). Revenue: kr2.55b (up 8.0% from 2Q 2023). Net income: kr72.0m (up 125% from 2Q 2023). Profit margin: 2.8% (up from 1.4% in 2Q 2023). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Jun 27
AddLife AB (publ) to Report Q1, 2025 Results on Apr 25, 2025 AddLife AB (publ) announced that they will report Q1, 2025 results at 7:45 AM, Central European Standard Time on Apr 25, 2025 Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Eva Elmstedt was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 09
AddLife AB (publ) Approves Dividend, Payable on 16 May 2024 AddLife AB (publ) at its Annual General Meeting held on 8 May 2024 approved the dividend of SEK 0.50 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed to be 13 May 2024. The dividend is expected to be remitted by Euroclear Sweden AB on 16 May 2024. Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: kr0.51 (vs kr1.43 in 1Q 2023) First quarter 2024 results: EPS: kr0.51 (down from kr1.43 in 1Q 2023). Revenue: kr2.57b (up 4.6% from 1Q 2023). Net income: kr62.0m (down 64% from 1Q 2023). Profit margin: 2.4% (down from 7.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • Apr 24
AddLife AB (publ) to Report Fiscal Year 2024 Results on Feb 05, 2025 AddLife AB (publ) announced that they will report fiscal year 2024 results on Feb 05, 2025 Recent Insider Transactions • Mar 13
Independent Director recently bought €2.8m worth of stock On the 7th of March, Håkan Roos bought around 315k shares on-market at roughly €9.06 per share. This transaction amounted to 9.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €4.2m more in shares than they have sold in the last 12 months. Announcement • Mar 06
AddLife AB (publ) to Report Fiscal Year 2023 Results on Apr 05, 2024 AddLife AB (publ) announced that they will report fiscal year 2023 results at 9:00 AM, Central European Standard Time on Apr 05, 2024 Declared Dividend • Feb 12
Dividend of kr0.50 announced Shareholders will receive a dividend of kr0.50. Ex-date: 10th May 2024 Payment date: 16th May 2024 Dividend yield will be 4.9%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 32%. Cash payout ratio: 13%. Reported Earnings • Feb 03
Full year 2023 earnings released: EPS: kr1.56 (vs kr3.94 in FY 2022) Full year 2023 results: EPS: kr1.56 (down from kr3.94 in FY 2022). Revenue: kr9.69b (up 6.6% from FY 2022). Net income: kr190.0m (down 60% from FY 2022). Profit margin: 2.0% (down from 5.3% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to €6.08, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Reported Earnings • Oct 28
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr2.32b (up 10% from 3Q 2022). Net income: kr25.0m (down 79% from 3Q 2022). Profit margin: 1.1% (down from 5.7% in 3Q 2022). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Announcement • Oct 27
AddLife AB (publ) to Report First Half, 2024 Results on Jul 15, 2024 AddLife AB (publ) announced that they will report first half, 2024 results on Jul 15, 2024 Buying Opportunity • Oct 26
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 39%. The fair value is estimated to be €5.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 18% in 2 years. Earnings is forecast to grow by 17% in the next 2 years. Announcement • Oct 20
AddLife AB (publ), Annual General Meeting, May 08, 2024 AddLife AB (publ), Annual General Meeting, May 08, 2024, at 16:00 Central European Standard Time. New Risk • Oct 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.2% net profit margin). Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to €6.80, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total loss to shareholders of 44% over the past three years. New Risk • Jul 20
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (9.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.2% net profit margin). Reported Earnings • Jul 14
Second quarter 2023 earnings released: EPS: kr0.27 (vs kr0.61 in 2Q 2022) Second quarter 2023 results: EPS: kr0.27 (down from kr0.61 in 2Q 2022). Revenue: kr2.37b (up 14% from 2Q 2022). Net income: kr33.0m (down 55% from 2Q 2022). Profit margin: 1.4% (down from 3.6% in 2Q 2022). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €10.08, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.38 per share. Recent Insider Transactions • May 28
Independent Director recently bought €1.0m worth of stock On the 22nd of May, Håkan Roos bought around 87k shares on-market at roughly €11.78 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €4.6m more in shares than they have sold in the last 12 months. Announcement • May 06
Addlife AB (Publ) Declares Dividend Addlife AB (Publ) declared a dividend of SEK 1.20 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed to be 8 May 2023. The dividend is expected to be remitted by Euroclear Sweden AB on 11 May 2023. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €10.55, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 34x in the Life Sciences industry in Europe. Total returns to shareholders of 54% over the past three years. Upcoming Dividend • Apr 28
Upcoming dividend of kr1.20 per share at 1.0% yield Eligible shareholders must have bought the stock before 05 May 2023. Payment date: 11 May 2023. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (0.7%). Reported Earnings • Apr 27
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr2.46b (down 4.7% from 1Q 2022). Net income: kr174.0m (down 23% from 1Q 2022). Profit margin: 7.1% (down from 8.7% in 1Q 2022). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 02
President & CEO recently bought €12k worth of stock On the 24th of March, Fredrik Dalborg bought around 2k shares on-market at roughly €8.27 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fredrik has been a buyer over the last 12 months, purchasing a net total of €49k worth in shares. Recent Insider Transactions • Mar 09
President & CEO recently bought €10.0k worth of stock On the 6th of March, Fredrik Dalborg bought around 1k shares on-market at roughly €9.99 per share. This transaction amounted to 8.0% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €26k. Fredrik has been a buyer over the last 12 months, purchasing a net total of €36k worth in shares. Reported Earnings • Feb 04
Full year 2022 earnings released: EPS: kr3.94 (vs kr6.02 in FY 2021) Full year 2022 results: EPS: kr3.94 (down from kr6.02 in FY 2021). Revenue: kr9.08b (up 14% from FY 2021). Net income: kr480.0m (down 33% from FY 2021). Profit margin: 5.3% (down from 9.0% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Feb 03
AddLife AB (publ) Proposes Dividend for the Year Ended December 31, 2022 The Board of directors of AddLife AB (publ) proposed a dividend of SEK 1.20 per share for the year ended December 31, 2022. Announcement • Nov 02
Håkan Roos acquired a 0.246285% stake in AddLife AB (publ) for SEK 30 million. Håkan Roos acquired a 0.246285% stake in AddLife AB (publ) for SEK 30 million on October 28, 2022. Following the transaction, Roos owns 2.2 million A shares and 3.2 million B shares in AddLife.
Håkan Roos completed the acquisition of a 0.246285% stake in AddLife AB (publ) on October 28, 2022. Reported Earnings • Oct 28
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr2.10b (up 14% from 3Q 2021). Net income: kr120.0m (down 13% from 3Q 2021). Profit margin: 5.7% (down from 7.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
AddLife AB (publ) to Report Q1, 2023 Results on Apr 26, 2023 AddLife AB (publ) announced that they will report Q1, 2023 results at 7:45 AM, Central European Standard Time on Apr 26, 2023 Buying Opportunity • Aug 30
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 37%. The fair value is estimated to be €16.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Earnings per share has grown by 51%. Revenue is forecast to grow by 1.9% in a year. Earnings is forecast to decline by 26% in the next year. Reported Earnings • Jul 16
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr2.08b (down 8.7% from 2Q 2021). Net income: kr74.0m (down 58% from 2Q 2021). Profit margin: 3.6% (down from 7.8% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 1.3%, compared to a 14% growth forecast for the industry in Germany. Buying Opportunity • Jul 02
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 44%. The fair value is estimated to be €17.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Earnings per share has grown by 59%. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment deteriorated over the past week After last week's 22% share price decline to €16.83, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total loss to shareholders of 29% over the past year. Recent Insider Transactions • Jun 06
CFO & Business Area Manager of Medtech recently sold €808k worth of stock On the 30th of May, Martin Almgren sold around 35k shares on-market at roughly €23.41 per share. This was the largest sale by an insider in the last 3 months. Martin has been a seller over the last 12 months, reducing personal holdings by €818k. Announcement • May 06
Addlife AB (Publ) Approves Dividend, Payable on 12 May 2022 AddLife AB (publ) announced that at the AGM held on 5 May 2022, the company announced that dividend of SEK 2.00 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed to be 9 May 2022. The dividend is expected to be remitted by Euroclear Sweden AB on 12 May 2022. Upcoming Dividend • Apr 29
Upcoming dividend of kr2.00 per share Eligible shareholders must have bought the stock before 06 May 2022. Payment date: 12 May 2022. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.0%). Higher than average of industry peers (0.6%). Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: kr6.02 (vs kr4.62 in FY 2020) Full year 2021 results: EPS: kr6.02 (up from kr4.62 in FY 2020). Revenue: kr7.99b (up 52% from FY 2020). Net income: kr718.6m (up 39% from FY 2020). Profit margin: 9.0% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.4%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany. Announcement • Apr 03
AddLife AB (publ) (OM: ALIF B) acquired O'Flynn Medical Limited. AddLife AB (publ) (OM: ALIF B) acquired O'Flynn Medical Limited on April 1, 2022. The company will become part of the Healthcare 21 Group, which AddLife acquired to the business area Medtech in 2021. O’Flynn Medical is an Irish company with annual net sales of approximately €6.4 million. O’Flynn Medical will form a bolt-on acquisition to healthcare 21 to complement existing product portfolios.
AddLife AB (publ) (OM: ALIF B) completed the acquisition of O'Flynn Medical Limited on April 1, 2022. Announcement • Mar 31
Addlife AB (Publ) Proposes Dividend, Payable on 12 May 2022 AddLife AB (publ) announced that at its Annual General Meeting to be held on 5 May 2022, the board of directors proposes to distribute SEK 2.00 per share, irrespectively of class of shares to the shareholders, and that 9 May 2022 shall be the record day for obtaining the dividend. The class B shares held by the Company are excluded from distribution of dividend. If the Annual General Meeting resolves in accordance with the proposal, the dividend is estimated to be distributed through the agency of Euroclear Sweden AB on 12 May 2022 to those who are registered in the share register on the record date. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improved over the past week After last week's 16% share price gain to €22.58, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 41% over the past year. Announcement • Mar 03
AddLife AB (publ) (OM:ALIF B) completed the acqusitions of Telia Health Monitoring. AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire Telia Health Monitoring on December 20, 2021. Telia Health and its eight employees will be integrated into Camanio, a subsidiary of AddLife. Completion is expected to take place in the first quarter of 2022.
AddLife AB (publ) (OM:ALIF B) completed the acqusitions of Telia Health Monitoring on March 1, 2022. Recent Insider Transactions • Feb 08
President & CEO recently bought €552k worth of stock On the 7th of February, Kristina Willgard bought around 30k shares on-market at roughly €18.40 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Kristina has been a net seller over the last 12 months, reducing personal holdings by €2.6m. Announcement • Feb 05
Addlife AB (Publ) Proposes Dividend AddLife AB (publ) announced Board of directors proposed a dividend of SEK 2.00 per share. Announcement • Feb 04
Addlife AB (Publ) Announces Step Down of Kristina Willgård as Chief Executive Officer AddLife AB (publ) announces Kristina Willgård has informed that she plans to step down as CEO. Announcement • Jan 22
AddLife AB (publ) (OM:ALIF B) completed the acquisition of MBA Incorporado S.A from Alantra Private Equity. AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire MBA Incorporado S.A from Alantra Private Equity for approximately €110 million on December 22, 2021. The transaction will be financed through extended credit facilities. MBA will operate as a separate subgroup and will be part of the Medtech business area. The transaction will be expected to be closed in January 2022.
AddLife AB (publ) (OM:ALIF B) completed the acquisition of MBA Incorporado S.A from Alantra Private Equity on January 20, 2022. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment deteriorated over the past week After last week's 23% share price decline to €27.86, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 87% over the past year. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improved over the past week After last week's 18% share price gain to €36.84, the stock trades at a trailing P/E ratio of 59.3x. Average trailing P/E is 50x in the Life Sciences industry in Europe. Total returns to shareholders of 184% over the past year. Announcement • Dec 23
AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire MBA Incorporado S.A from Alantra Private Equity for approximately €110 million. AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire MBA Incorporado S.A from Alantra Private Equity for approximately €110 million on December 22, 2021. The transaction will be financed through extended credit facilities. MBA will operate as a separate subgroup and will be part of the Medtech business area. The transaction will be expected to be closed in January 2022. Announcement • Dec 22
AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire Telia Health Monitoring. AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire Telia Health Monitoring on December 20, 2021. Telia Health and its eight employees will be integrated into Camanio, a subsidiary of AddLife. Completion is expected to take place in the first quarter of 2022. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €28.90, the stock trades at a trailing P/E ratio of 51.2x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total returns to shareholders of 140% over the past year. Recent Insider Transactions • Oct 30
President & CEO recently sold €3.2m worth of stock On the 26th of October, Kristina Willgard sold around 90k shares on-market at roughly €35.19 per share. In the last 3 months, there was an even bigger sale from another insider worth €41m. This was Kristina's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improved over the past week After last week's 17% share price gain to €36.16, the stock trades at a trailing P/E ratio of 56.9x. Average trailing P/E is 55x in the Life Sciences industry in Europe. Total returns to shareholders of 201% over the past year. Reported Earnings • Oct 23
Third quarter 2021 earnings released The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: kr1.85b (up 49% from 3Q 2020). Net income: kr138.0m (up 9.5% from 3Q 2020). Profit margin: 7.5% (down from 10% in 3Q 2020). The decrease in margin was driven by higher expenses. Recent Insider Transactions • Sep 22
Independent Chairman recently sold €1.1m worth of stock On the 17th of September, Johan Sjo sold around 30k shares on-market at roughly €37.08 per share. In the last 3 months, there was an even bigger sale from another insider worth €41m. Johan has been a seller over the last 12 months, reducing personal holdings by €1.8m. Announcement • Sep 02
AddLife AB (publ) (OM:ALIF B) acquired Bio-Connect BV. AddLife AB (publ) (OM:ALIF B) acquired Bio-Connect BV on September 1, 2021. For the year ending December 31, 2020, Bio-Connect BV reported turnover of approximately €14 million. The transaction is expected to have only a marginal positive effect on AddLife’s earnings per share in the 2021 financial year.
AddLife AB (publ) (OM:ALIF B) completed the acquisition of Bio-Connect BV on September 1, 2021. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 17% share price gain to €33.76, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 58x in the Life Sciences industry in Europe. Total returns to shareholders of 146% over the past year. Recent Insider Transactions • Aug 08
Independent Chairman recently sold €689k worth of stock On the 5th of August, Johan Sjo sold around 23k shares on-market at roughly €29.44 per share. This was the largest sale by an insider in the last 3 months. Johan has been a seller over the last 12 months, reducing personal holdings by €902k. Reported Earnings • Jul 16
Second quarter 2021 earnings released: EPS kr1.46 (vs kr1.07 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: kr2.28b (up 82% from 2Q 2020). Net income: kr177.0m (up 49% from 2Q 2020). Profit margin: 7.8% (down from 9.5% in 2Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment improved over the past week After last week's 16% share price gain to kr29.50, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 59x in the Life Sciences industry in Europe. Total returns to shareholders of 181% over the past year. Recent Insider Transactions • May 09
Chief Financial Officer recently sold €1.4m worth of stock On the 7th of May, Martin Almgren sold around 64k shares on-market at roughly €22.35 per share. This was the largest sale by an insider in the last 3 months. Martin has been a seller over the last 12 months, reducing personal holdings by €1.5m. Executive Departure • May 08
Independent Director has left the company On the 6th of May, Andreas Göthberg's tenure as Independent Director ended after 2.9 years in the role. We don't have any record of a personal shareholding under Andreas' name. Andreas is the only executive to leave the company over the last 12 months. Announcement • May 06
AddLife AB (publ) Approves Dividend, Payable on 12 May 2021 AddLife AB (publ) announced that at the AGM held on 5 May 2021, the company approved a dividend of SEK 1.50 per share, irrespectively of class of shares. Record date for the dividend was confirmed to be 7 May 2021. The dividend is expected to be remitted by Euroclear Sweden AB on 12 May 2021. Reported Earnings • Apr 30
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr1.74b (up 65% from 1Q 2020). Net income: kr226.0m (up 319% from 1Q 2020). Profit margin: 13% (up from 5.1% in 1Q 2020). The increase in margin was driven by higher revenue. Upcoming Dividend • Apr 29
Upcoming dividend of kr1.50 per share Eligible shareholders must have bought the stock before 06 May 2021. Payment date: 12 May 2021. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (3.2%). Higher than average of industry peers (0.5%). Announcement • Apr 13
AddLife AB (Publ) Provides Earnings Guidance for 2021 AddLife AB (publ) provides earnings guidance for 2021. Pro-forma sales excluding non-recurring revenue are estimated to be approximately EUR 153 million and pro-forma EBITA approximately EUR 18.5 million. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improved over the past week After last week's 20% share price gain to kr17.88, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 52x in the Life Sciences industry in Europe. Total returns to shareholders of 151% over the past year. Reported Earnings • Apr 03
Full year 2020 earnings released: EPS kr4.62 (vs kr1.27 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr5.27b (up 52% from FY 2019). Net income: kr517.8m (up 268% from FY 2019). Profit margin: 9.8% (up from 4.0% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Mar 04
New 90-day high: €17.50 The company is up 45% from its price of €12.11 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 13% over the same period. Reported Earnings • Feb 05
Full year 2020 earnings released: EPS kr4.62 (vs kr1.27 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr5.27b (up 52% from FY 2019). Net income: kr518.0m (up 268% from FY 2019). Profit margin: 9.8% (up from 4.0% in FY 2019). The increase in margin was driven by higher revenue. Announcement • Feb 04
AddLife AB (publ) to Report Fiscal Year 2021 Results on Feb 03, 2022 AddLife AB (publ) announced that they will report fiscal year 2021 results on Feb 03, 2022 Is New 90 Day High Low • Feb 03
New 90-day high: €16.04 The company is up 21% from its price of €13.30 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 5.0% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: €15.21 The company is up 9.0% from its price of €13.97 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 5.0% over the same period.